Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
CTRC-AACR SABCS Annual Meeting
SWOG: Two Hormonal Agents Extend Survival over Anastrozole Alone in Metastatic Breast Cancer
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
;Two antiestrogen agents may be better than one in the treatment of metastatic hormone receptor-positive breast cancer patients, according to a study conducted by the Southwest Oncology Group (SWOG) clinical trials network and presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
New Prognostic Tool to Guide Treatment of Ductal Carcinoma In Situ
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
Read Article
Adding Everolimus to Exemestane Significantly Prolongs Remission in Patients with Breast Cancer
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
Read Article
Role of Adjuvant Zoledronic Acid in Endocrine Receptor-Positive Breast Cancer Being Refined
By
Phoebe Starr
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
Read Article
Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression
By
Caroline Helwick
CTRC-AACR SABCS Annual Meeting
December 2011, Vol 2, No 7
San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma